DrugDashboards

Pomalidomide

Pomalidomide · POMALIDOMIDE 3 mg/1 · Capsule · Oral · Teva Pharmaceuticals, Inc.

NDC 00480-2601-21 · 21 CAPSULE in 1 BOTTLE · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 59572-0503-21) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$1,173.76per unit
middle half $1,137.66–$1,209.62 · 2,704 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $1,173.76
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
49%of plans cover it
tier 5 · prior auth 100% · step therapy 0% · qty limit 91%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $21,797.01 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · PS-Pomalidomide Shared System REMS

Regulatory

Application
ANDA209956
TE code
AB
Approval date
May 4, 2022
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Pomalidomide (Capsule)

LabelerStrengthFirst seenLast seen
Cipla USA Inc.POMALIDOMIDE 2 mg/1Sep 3, 2026Sep 3, 2026
Cipla USA Inc.POMALIDOMIDE 3 mg/1Sep 3, 2026Sep 3, 2026
Cipla USA Inc.POMALIDOMIDE 4 mg/1Sep 3, 2026Sep 3, 2026
Cipla USA Inc.POMALIDOMIDE 1 mg/1Sep 3, 2026Sep 3, 2026
Dr. Reddy's Laboratories Inc.POMALIDOMIDE 1 mg/1Sep 3, 2026Sep 3, 2026
Dr. Reddy's Laboratories Inc.POMALIDOMIDE 2 mg/1Sep 3, 2026Sep 3, 2026
Dr. Reddy's Laboratories Inc.POMALIDOMIDE 4 mg/1Sep 3, 2026Sep 3, 2026
Dr. Reddy's Laboratories Inc.POMALIDOMIDE 3 mg/1Sep 3, 2026Sep 3, 2026
Sandoz IncPOMALIDOMIDE 1 mg/1Sep 3, 2026Sep 3, 2026
Sandoz IncPOMALIDOMIDE 3 mg/1Sep 3, 2026Sep 3, 2026
Sandoz IncPOMALIDOMIDE 2 mg/1Sep 3, 2026Sep 3, 2026
Sandoz IncPOMALIDOMIDE 4 mg/1Sep 3, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.POMALIDOMIDE 3 mg/1Sep 3, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.POMALIDOMIDE 1 mg/1Sep 3, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.POMALIDOMIDE 4 mg/1Sep 3, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.POMALIDOMIDE 2 mg/1Sep 3, 2026Sep 3, 2026
Apotex Corp.POMALIDOMIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.POMALIDOMIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.POMALIDOMIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.POMALIDOMIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedPOMALIDOMIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedPOMALIDOMIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedPOMALIDOMIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedPOMALIDOMIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.POMALIDOMIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.POMALIDOMIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.POMALIDOMIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.POMALIDOMIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.POMALIDOMIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.POMALIDOMIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.POMALIDOMIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.POMALIDOMIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Celgene CorporationPOMALIDOMIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Celgene CorporationPOMALIDOMIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Celgene CorporationPOMALIDOMIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Celgene CorporationPOMALIDOMIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedPOMALIDOMIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedPOMALIDOMIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedPOMALIDOMIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Natco Pharma LimitedPOMALIDOMIDE 2 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Pomalidomide — NDC 00480-2601-21," retrieved September 3, 2026, https://drugdashboards.com/drug/00480260121.

Free to cite with attribution — see how the data is put together.